European Pharmaceutical Review

JUNE 28, 2022

billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 percent CAGR between 2022 and 2026. The Asia-Pacific market is expected to grow the most in years to come, as people’s income rises, healthcare expenditure grows and the population expands. YMC Europe GmbH.

Marketing 111

Marketing Government Healthcare Healthcare 111

European Pharmaceutical Review

JULY 21, 2023

The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. They drive competition and cost savings, helping to address the rising financial pressures faced by global healthcare systems.

Biopharma 98

Biopharma Manufacturing Competition Healthcare 98

European Pharmaceutical Review

SEPTEMBER 7, 2022

The 2022-2026 workplan of the initiative Accelerating Clinical Trials in the EU ( ACT EU ) has been published by the European Commission (EC), Heads of Medicines Agencies (HMA) and European Medicines Agency (EMA). implementing the CTR – focus on CTIS and CTR training activities and trouble-shooting any issues encountered by trial sponsors.

Medicine 105

Medicine Training Networking Pharmaceutical 105

pharmaphorum

JANUARY 29, 2023

With the population ageing, the need for healthcare is growing fast: between 2015 and 2050, the proportion of the world’s population over 60 years old will nearly double from 12% to 22%, according to the World Health Organization. Secondly, pressure on healthcare spending is leading to greater consolidation.

Healthcare 98

Healthcare Healthcare Manufacturing Marketing 98

European Pharmaceutical Review

NOVEMBER 24, 2022

Tackling pharmaceutical counterfeiting continues, therefore, to be a clear and present priority for manufacturers, healthcare authorities and law enforcement. One area in which the problem can be tackled effectively is product packaging. Quality assurances through the use of holograms.

Pharmaceutical 111

Pharmaceutical Manufacturing Pharmaceutical products Distribution 111

European Pharmaceutical Review

AUGUST 17, 2022

The WuXi STA Middletown site is located in the Middletown Business Center at 1091 Industrial Drive and facility will create approximately 500 full-time jobs by 2026. WuXi STA has 12 sites across the US, Europe and Asia. The WuXi STA Middletown facility is expected to begin operations in 2025.

Manufacturing 96

Manufacturing Pharmaceutical manufacturing Distribution Pharmaceutical 96

European Pharmaceutical Review

MARCH 24, 2023

Thus, regulators needed to be ready to support the development and assessment of ever more complex medicines that increasingly deliver healthcare solutions by converging different technologies. A final report on the regulatory science strategy will be published in 2026, once the strategy has been completed.

Medicine 96

Medicine Consulting Networking Safety 96

European Pharmaceutical Review

SEPTEMBER 15, 2023

Revolutionising microencapsulation with in-air microfluidics technology for next-generation sustainable healthcare solutions. .: Revolutionising microencapsulation with in-air microfluidics technology for next-generation sustainable healthcare solutions. CUBIC CRO Service Dr Ferrer Biopharma: GentleMist Technology IamFluidics B.V.:

Pharma 119

Pharma Manufacturing Biopharma Pharmaceutical 119

Pharmaceutical Technology

JULY 26, 2022

The SPAC is sponsored by a Frazier Healthcare Partners affiliate. Through an oversubscribed and upsized private investment in public equity (PIPE) led jointly by Frazier Healthcare Partners and Bain Capital Life Sciences, the combined business is expected to receive nearly $235m and funds held in the trust account of FLAC.

Pharma 59

Pharma Specialization Healthcare Healthcare 59

European Pharmaceutical Review

NOVEMBER 12, 2024

To boost AstraZeneca’s research and manufacturing footprint by the end of 2026, it is dedicating $3.5 billion of capital investment in the US. Of this amount, $2 billion will generate over 1,000 new jobs, the company added.

Manufacturing 59

Manufacturing Biopharma Healthcare Healthcare 59

Clarify Health

APRIL 26, 2022

Artificial intelligence (AI) has the potential to affect healthcare in profound ways — propelling better data-driven decisions on diagnoses, treatments, and population health management. health system realize $150 billion in savings by 2026. During the panel, Dr. Ramadoss gave examples of AI applications in healthcare.

Healthcare 52

Healthcare Healthcare Management Media 52

PM360

SEPTEMBER 28, 2022

By 2026, the U.S. The consequences for the health industry are huge—especially considering the Hispanic population is traditionally considered a “healthcare powerhouse.” Roughly 62% prefer healthcare information resources in Spanish, while 67% say their cultural heritage influences their purchase decisions. Census estimates 69.7

Patients 98

Patients Marketing Doctors Healthcare 98

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. billion by 2026, according to research by the Business Research Company. billion in 2021 to $9.23 References.

Marketing 98

Marketing Pharma Healthcare Healthcare 98

PM360

SEPTEMBER 21, 2023

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

European Pharmaceutical Review

FEBRUARY 12, 2024

Indeed, optimisation of the process and investment in new technologies has enabled the site to further enhance manufacturing capabilities to triple output annually, meaning more patients can avail of potentially life-changing medicines – and the facility is now targeting to serve 650,000 patients annually by 2026,” says Dunne.

Manufacturing 98

Manufacturing Medicine Leads Patients 98

Pharmaceutical Technology

MAY 29, 2023

GlobalData’s Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 report offers insights on application of blockchain in healthcare and other key sectors.

Pharmaceutical 52

Pharmaceutical Marketing Competition Medicine 52

European Pharmaceutical Review

SEPTEMBER 26, 2023

Multiple sclerosis is a chronic condition with no cure at present and timely access to affordable, high-quality healthcare is therefore even more essential.” The site is planned to be completed by 2026. The authorisation was also granted as treatment for other forms of the disease.

Food and Drug Administration 59

Food and Drug Administration Medicine Distribution Food 59

PM360

SEPTEMBER 21, 2023

Starting in 2026, the provision will affect 10 Part D drugs. This increases to 15 Part D drugs in 2026, as well as 15 Part B and D drugs in 2028, and a full 20 Part B and D drugs in 2029. Casberg said his company is getting many queries from payers and PBMs about these issues.

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

MAY 4, 2023

Dianthus has received a private investment commitment of $70m in its common stock and pre-funded warrants from a group of healthcare investors including the Fidelity Management & Research Company, Catalio Capital Management, 5AM Ventures and Avidity Partners. These cash resources will fund the business into mid-2026.

Management 52

Management Healthcare Healthcare 52

Pharmaceutical Technology

OCTOBER 14, 2022

This cash will be used to advance Enliven’s pipeline of candidates through multiple clinical milestones while providing runway into early 2026. Co-led by new investors Venrock Healthcare Capital Partners and Fairmount, the financing has also seen participation from several new investors.

Management 52

Management Pharmaceutical Healthcare Healthcare 52

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Penrod

APRIL 1, 2024

What CMS-0057-F Means for Health Insurance Companies In January 2024, CMS finalized its interoperability and prior authorization rule that requires various healthcare insurance entities to abide by the latest electronic health information exchange and prior authorization process for clinical services.

Electronics 52

Electronics Insurance Healthcare Healthcare 52

Infuse Medical

JULY 4, 2024

VR in healthcare is doing magic by transforming the conventional working environment to the next level. Brief Overview of the Importance of Medical Device Maintenance Medical device maintenance ensures patient safety, operational efficiency, and regulatory compliance in healthcare settings. billion by 2026. What is VR Training?

Training 52

Training Medical Healthcare Healthcare 52

pharmaphorum

JULY 26, 2022

The Dutch biotech will book around $235 million from a private placement led by Frazier Healthcare Partners and Bain Capital Life Sciences and funds held in Frazier’s trust account.

Side effects 52

Side effects Safety Pharma Patients 52

pharmaphorum

JANUARY 18, 2023

AI-based medical imaging was a market worth more than $400 million in 2021, according to figures cited by Bayer, and is expected to have a compound annual growth rate (CAGR) of more than 26% between 2020 to 2026, driving its value to around $1.36 billion) in 2021, around 10% of the group’s total healthcare revenues.

Medical 59

Medical Pharma Media Sales 59

PM360

APRIL 7, 2023

Most immediately, it will add confusion in the healthcare space,” explains Daniel Sontupe, Associate Partner, Managing Director, The Bloc Value Builders. This will create confusion in the marketplace and may possibly lead to delivery of misinformation to healthcare providers (HCPs) regarding a brand’s drug coverage,” Bambalas says.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Clarify Health

MAY 4, 2022

Population health management is best supported by a data-driven approach with a structured analytics process driven by skilled and competent healthcare leaders and clinicians. Reports estimate that the healthcare analytics market size is expected to grow to $75.1 billion by 2026.

Management 52

Management Healthcare Healthcare Training 52

Clarify Health

MAY 4, 2022

Population health management is best supported by a data-driven approach with a structured analytics process driven by skilled and competent healthcare leaders and clinicians. Reports estimate that the healthcare analytics market size is expected to grow to $75.1 billion by 2026.

Management 52

Management Healthcare Healthcare Training 52

Medico Reach

MARCH 24, 2023

As a result, a global approach to healthcare has emerged continually over the years. This global approach to healthcare is known as precision medicine which has emerged in treatments like immunotherapy. It is estimated that global oncology spending will exceed $300 billion by 2026.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Medico Reach

MARCH 24, 2023

As a result, a global approach to healthcare has emerged continually over the years. This global approach to healthcare is known as precision medicine which has emerged in treatments like immunotherapy. It is estimated that global oncology spending will exceed $300 billion by 2026.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. United States Specialty Pharmaceuticals Market & Forecast 2020-2026,” BusinessWire, December 8, 2020. IQVIA Institute, March 2022.

Prescription 52

Prescription Medical Patients Distribution 52

PM360

FEBRUARY 1, 2024

Confidence Amidst Funding Challenges The resilience and confidence observed amidst funding challenges within the biotech sector represent a testament to the industry’s steadfast commitment to innovation and transformative advancements in healthcare.

Recruitment 52

Recruitment Healthcare Healthcare Management 52

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. That impacts launches most. Lastly, the growing economic crisis creates increasing challenge for medicines funding.

Doctors 59

Doctors Medicine Marketing Sales 59

Pharmaceutical Technology

JANUARY 31, 2023

FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. That leaves three years for pharma companies to prepare.

FDA 52

FDA Prescription Medicine Biopharma 52

Clarivate

OCTOBER 31, 2023

Plenty of biotech companies are happy to take a pharma deal presently to extend their financial runway into 2024, 2025, and 2026, said Williamson, “and if that means not retaining significant rights, so be it.”

Pharma 52

Pharma Biopharma Marketing Healthcare 52

Clarivate

AUGUST 27, 2024

Abbott’s Volt should join the party in early 2026. Still, analysts and providers project that Farapulse, which has more than 70% of the global market today, will continue to dominate at least through 2025. Companies of interest in this regard include Atricure Inc., Pulse Biosciences Inc., Adagio Medical Inc., Acutus Medical Inc.,

Marketing 52

Marketing Competition FDA Electronics 52

European Pharmaceutical Review

FEBRUARY 7, 2023

Edward Turtle is a products lawyer, regulatory advisor and litigator with particular experience in the healthcare, technology and consumer product sectors. of the MDR and Article 110.4 of the IVDR for medical devices and in vitro diagnostic medical devices (IVDs).

Medical 117

Medical Government Marketing Medicine 117